Breaking News

CMC Biologics Adds Single-Use Facility

August 25, 2010

CMC Biologics has completed a new disposable manufacturing facility at its Seattle, WA site.

CMC Biologics has completed a new disposable manufacturing facility at its Seattle, WA site. The addition is part of a major expansion to add production capacity to its existing facility for the cGMP manufacture of biopharmaceuticals.

The multi-purpose, single-use facility will allow for early-phase clinical manufacture of biopharmaceuticals including monoclonal antibodies and other mammalian cell culture-based recombinant proteins. CMC has partnered with Hyclone to supply the new disposable facility with processing equipment, including a 100L and two 500L single-use bioreactors (SUBs) and disposable mixers.

CMC Biologics also continues to offer its stainless-steel clinical and commercial cGMP manufacturing facility, at which the company is increasing capacity with the addition of a second 3000L bioreactor train.

"Disposable technology offers the advantages of increased flexibility and efficiency, decreased cross-contamination risks, and elimination of cleaning, sterilization and other change-over procedures typically associated with traditional steel tank facilities, while providing the same performance," said Andy Walker, senior director of manufacturing at CMC. "Consequently, it provides a cost-effective strategy for reducing the speed to market for many biologics."

Gustavo Mahler, president and chief operating officer, added, "As process yields continue to increase through advances in protein expression, cell culture, and purification technologies, the need for costly high-volume stainless steel tank facilities will decline for some products. We believe this trend will continue to push bioprocessing toward single-use technology."

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks